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To understand and compare the mechanisms of murine and human PV infection, we examined
pseudovirion binding and infection of the newly described MusPV1 using the murine cervicovaginal
challenge model. These analyses revealed primary tissue interactions distinct from those previously
described for HPV16. Unlike HPV16, MusPV1 bound basement membrane (BM) in an HSPG-independent
manner. Nevertheless, subsequent HSPG interactions were critical. L2 antibodies or low doses of VLP
antibodies, sufﬁcient to prevent infection, did not lead to disassociation of the MusPV1 pseudovirions
from the BM, in contrast to previous ﬁndings with HPV16. Similarly, furin inhibition did not lead to loss
of MusPV1 from the BM. Therefore, phylogenetically distant PV types differ in their initial interactions
with host attachment factors, but initiate their lifecycle on the acellular BM. Despite these differences,
these distantly related PV types displayed similar intracellular trafﬁcking patterns and susceptibilities to
biochemical inhibition of infection.
Published by Elsevier Inc.
Introduction
Papillomaviruses (PVs) are a family of small, non-enveloped
viruses that infect humans and many other vertebrate species. PVs
infect mucosal and cutaneous squamous epithelia, where they
cause disease by stimulating epithelial proliferation (Howley et al.,
2013). Despite similarity in genomic organization and capsid
structure, productive infection with PVs is generally species-
speciﬁc (Chan et al., 1992; Parsons and Kidd, 1942). The 8 kb PV
genome is encapsidated within a 55–60 nm non-enveloped capsid
comprised of two virion proteins. There are 360 copies of L1, the
major capsid protein, arranged into 72 capsomers. Each of these
capsomers may contain one copy of L2, the minor capsid protein
(Buck et al., 2005b). L1 can assemble in the absence of L2 to
produce non-infectious virus-like particles (VLPs). VLPs are able to
attach and enter cultured cells similarly to infectious virus (Day
et al., 2003). Therefore, L2 is not considered to play a role in the
initial attachment of the virus, although it may interact with cell
surface proteins following capsid attachment (Kawana et al., 2001;
Woodham et al., 2012; Yang et al., 2003). Furin/proprotein con-
vertase activation of L2 precedes endocytosis and is essential for
efﬁcient infection (Richards et al., 2006). L2 is also essential for the
successful delivery of the genome to nucleus (Day et al., 2004).
Studies of the early events in PV infectious entry have produced
different results, depending on the in vitro or in vivo model system
utilized. Monolayer cell culture has been instrumental to the basic
understanding of PV binding and entry. Although a consensus model
has not yet been achieved, multiple independent studies utilizing
pseudovirus (PsV) indicate an initial interaction with HSPGs, furin
cleavage of L2 and internalization via a non-clathrin, non-caveolar
pathway that most closely resembles macropinocytosis (Cerqueira
et al., 2013; Day et al., 2008; Giroglou et al., 2001; Joyce et al., 1999;
Knappe et al., 2007; Schelhaas et al., 2012; Selinka et al., 2007, 2003;
Spoden et al., 2008). Despite the advances afforded from in vitro
studies, cells adapted to long-term culture have undergone numer-
ous modiﬁcations and may not adequately reﬂect the in vivo
situation. We have recently utilized a murine cervicovaginal chal-
lenge (CVC) model to dissect early in vivo infection events (Kines
et al., 2009). The initial description of this model identiﬁed a
requirement for epithelial wounding and access to the acellular
basement membrane (BM) for initial capsid binding (Roberts et al.,
2007). The interpretation was that epithelial cells were infected as
they migrated over the BM during the wound healing process.
Further analysis of HPV16 PsV infection in this system allowed us to
compare parameters of in vitro and in vivo infection. These studies
identiﬁed several differences between the systems, with the most
signiﬁcant being that the initial HSPG-dependent capsid binding and
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furin cleavage occurs on the BM in vivo, prior to interaction with the
epithelial cells, whereas in vitro these events can occur on the cell
membrane (Day et al., 2008, 2012). The recent identiﬁcation of a
mouse papillomavirus, MusPV1 (also termed MmuPV1) (Ingle et al.,
2011), now allows us to utilize the murine model with a homologous
virus type. Although this eliminates the caveat of a heterologous
virus-host system, the fact that MusPV1 is presumably a cutaneous
type must be considered if differences in initial host interactions
were detected in comparison to the mucosotropic HPV16. Based on
its phylogeny, MusPV1 is a member of the BetaþXi-PV super taxon
within the genus Pi-PV, which is phylogenetically distant from the
alpha genus human types (Schulz et al., 2012). Indeed the interac-
tion of HPV5, a cutaneous beta human type, with speciﬁc HSPGs has
been shown to differ relative to that of the mucosotropic alpha
types, HPV16, HPV31 and HPV45 (Johnson et al., 2009). Additionally
carrageenan, a highly sulfated polysaccharide, does not efﬁciently
prevent infection with HPV5 PsV in vitro, whereas picomolar
concentrations block infection with all examined mucosotropic
types (Buck et al., 2006).
In this study, we have detailed the binding and infection events of
MusPV1 PsV in the murine CVC model and compared these interac-
tions to those of HPV16. As with HPV16, we ﬁnd that MusPV1 PsV
infection is initiated on the BM, conﬁrming the importance of this
extracellular site in the PV lifecycle. Infection can be prevented by the
addition of exogenous heparin and by furin inhibition. However, the
mechanism of inhibition is apparently different, revealing a non-HSPG
binding factor for MusPV1 on the murine BM.We have also compared
the binding and entry of these viruses in vitro, in cultured keratino-
cytes of both human and murine origin. The two virus types exhibited
no differences in their proﬁles of biochemical inhibition among the
cell types examined. However, the cells of murine and human origin
exhibited marked variations in these proﬁles.
Results
Examination of MusPV1 interactions in vivo
Utilizing the murine CVC model, we examined the interaction of
MusPV1 pseudovirions with host tissue. We have previously estab-
lished that MusPV1 pseudovirions are infectious in the CVC model
and require tissue disruption similarly to infection with HPV16 and
other HPV pseudovirions (Handisurya et al., 2012; Roberts et al.,
2007). Here we found that MusPV1 particles bound to the acellular
basement membrane (BM) at an early time point (4 h) and were
found associated with epithelial cells following re-epithelialization
(18 h) (Fig. 1, panels A and B). These tissues were co-stained with an
antibody recognizing nidogen to delineate the BM. This association of
the capsids with the BM at early time points and their relocalization
to the epithelium at later time points replicates our ﬁndings with
HPV16 (Kines et al., 2009). In that study, we demonstrated that HPV16
interacted with HSPG on the BM and that cleavage of HS moieties
with heparinase III prevented binding of HPV16 capsids to the BM and
subsequent infection. In contrast, we found here that heparinase III
treatment did not affect the in vivo infectivity of MusPV1, although
the control experiments clearly showed the previously described
diminution of HPV16 infection (Fig. 2A). We examined the distribu-
tion of MusPV1 capsid binding at 4 h post-instillation either in the
presence of heparinase digestion buffer as a negative control (Fig. 1C)
or following heparinase III digestion (Fig. 1D). Heparinase treatment
did not visibly affect the interaction of capsids with the BM. To
conﬁrm that heparinase treatment resulted in efﬁcient removal of HS
moieties from the BM, we stained these tissues with an anti-HS
antibody coincidently with anti-L1 staining. This analysis showed
clearly that MusPV1 bound well to BM that exhibited no detectable
anti-HS reactivity (Supplemental Fig. 2).
Although it is unlikely that the initial interaction of the MusPV1
capsid is to BM HSPG, it was unclear from this experiment
whether HSPG interactions subsequent to the initial BM interac-
tion might be critical, as HS moieties would be regenerated by the
tissue during the time course of the infection. Their regeneration
could allow transfer of BM-bound virions to newly synthesized
HSPG; indeed the increased infection observed with MusPV1
following heparinase digestion (Fig. 2A) may reﬂect this propen-
sity. Therefore, we decided to examine the effect of exogenous
heparin, an established competitor for HSPG interaction, on in vivo
MusPV1 infection, reasoning that the pre-association of heparin
with the capsids could prevent a putative heparin-dependent step
that occurs subsequent to the initial BM interaction. As shown in
Fig. 2B, the instillation of exogenous heparin did repress in vivo
infection by MusPV1. This observation probably implies the
existence of an HSPG-dependent step in infection subsequent to
the HSPG-independent BM binding. Consistent with this possibi-
lity, heparin, like heparinase III treatment, did not noticeably affect
the initial binding of the particles with the BM (Fig. 1E). By
contrast, at 18 h post-instillation, the heparin-treated capsids were
not found in association with the epithelium (Fig. 1F), unlike the
untreated capsids (Fig. 1B).
We reasoned that heparin inhibition might not result in a durable
decrease in infection, as the initial tissue binding is not prevented
and heparin may possibly dissociate from the capsid over time,
allowing infection to progress. Therefore we examined infection at
48 and 72 h post-infection. A marginal increase in infection by 72 h
was observed. HPV16 infection remained unchanged during this
time. As expected in the event of infection, MusPV1 capsid associa-
tion with the vaginal epithelium was detectable at these later time
points (data not shown).
MusPV1 infection is furin-dependent
All PV PsV examined so far have been found to require furin for
in vitro infection, and the furin-dependence of in vivo HPV16
infection has been established (Kines et al., 2009; Richards et al.,
2006). Furin cleaves the amino terminus of the L2 protein during
infectious entry in cultured cells and on the BM in vivo, and in vivo
inhibition of furin cleavage of HPV16 capsids results in their
premature release from the BM. Our working model of in vivo
HPV16 infection suggests that furin cleavage of L2 induces a
change in capsid morphology that results in exposure of a buried
neutralization epitope on L2 and a secondary receptor binding
site(s) on L1. Exposure of this putative L1 site(s) allows for stable
association with the epithelial target cells, and inhibition of furin
cleavage prevents this association. However, reduced afﬁnity for
the BM HSPG causes loss of the HPV16 capsids from the tissue
(reviewed in Day and Schiller (2009)).
Given that the initial in vivo interactions of MusPV1 appeared to
differ from those of HPV16, we examined the effects of furin
inhibition on MusPV1 infection. After conﬁrming that in vitro infec-
tion with MusPV1 PsV was inhibited with decanoyl-RVKR-cmk, a
potent inhibitor of furin and other proproteins convertases (data
shown as part of Fig. 9), we then determined that it also inhibited
in vivo MusPV1 infection, similarly to HPV16 (Fig. 2C). However, when
we examined the distribution of MusPV1 capsids within the murine
genital tract in the presence of the furin inhibitor, we found extensive
association with the BM at both the 4 h (Fig. 3A) and 18 h time points
(Fig. 3B). Although the 4 h time point result is similar to what we have
observed with HPV16, the HPV16 capsids are lost from the BM by the
18 h time point under conditions of furin inhibition. Consistent with
the ability of the furin inhibitor to prevent MusPV1 infection,
decanoyl-RVKR-cmk treatment did not result in the detectable
transfer of capsids to the epithelium seen at the 18 h time point,
unlike the untreated capsids at this time (Fig. 1B). Therefore, the
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inhibition of infection does not derive from the loss of capsids from
the tissue, but from their inability to be transferred from the BM to
the epithelium. This step represents another point of divergence
between the in vivo infection processes of MusPV1 and HPV16.
L2 exposure on the BM
With HPV16, inhibition of furin cleavage of L2 prevents exposure
of the N-terminus of L2, which occurs on the BM (Kines et al., 2009).
To determine if MusPV1 is also governed by this process, we
generated a rabbit polyclonal serum against the MusPV1 L2 peptide
spanning amino acids 17–36. To ensure speciﬁcity of this detection,
we compared the staining with pre-immune serum in infected
tissue with that observed with the immune serum (Fig. 3C). As a
further control for speciﬁc binding to the temporally-exposed L2
epitope, we stained tissues at 4 h post-inoculation. It was previously
shown, for HPV16, that little L2 had undergone the necessary
conformational change(s) to allow epitope exposure. Similarly to
HPV16, no anti-L2 binding was seen at this time point for MusPV1
(Fig. 3D), although clear capsid association was demonstrated with
anti-L1 staining (Fig. 3E and F, merged image). Although these
experiments did not result in an observable signal, L2 was readily
Fig. 1. Interactions of MusPV1 within the murine vaginal tract. The binding of MusPV1 capsids was detected with rabbit anti-MusPV1 antiserum, shown in the green channel
in all images. The red channel depicts the staining with a rat anti-nidogen antiserum. This delineates the BM. Nidogen is also present around dermal lymphatic vessels,
obvious in panels B, E and F. The binding of untreated MusPV1 capsids at 4 h post-instillation is shown in panel A. At this time colocalization to the denuded BM is evident.
The binding at 18 h post-instillation is shown in panel B. During the wound healing process epithelial cells from the unwounded vicinity have migrated over the denuded
BM. Capsids are associated with these cells above the BM. Panel C shows the capsid binding following instillation of heparinase digestion buffer. Panel D shows the binding
following heparinase digestion. The binding of heparin-treated MusPV1 capsids 4 h after instillation is shown in panel E. The binding of the heparin-treated capsids at 18 h is
shown in panel F. Comparison of this pattern to panel B shows clear sequestration of the capsids on the BM. Higher magniﬁcation insets have been included in these two
panels to allow easier visualization.
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seen at 18 h after infection (Fig. 3G, green channel) that colocalized
with a rat antiserum raised against MusPV1 L1 VLPs (Fig. 3H, red
channel; Fig. 3I, merged image). The L2 signal was associated with
the same BM regions as the L1 staining and showed clear epithelial
association only in this area. In contrast, the intensity of the L2
staining was decreased in the presence of furin inhibitor (Fig. 3J–L).
There was minimal exposure of the 17–36 epitope at 18 h with this
treatment (Fig. 3J, green channel), although there was clear capsid
binding to the BM (Fig. 3K, red channel; Fig. 3L, merged image).
Thus, L2 exposure on the BM and its dependence on furin are
features that are shared by HPV16 and MusPV1 infection.
Neutralization of in vivo MusPV1 infection
PV infection can be effectively neutralized with type-speciﬁc
anti-L1 VLP antibodies (Carter et al., 2006; Wang et al., 2003),
while broader protection across PV types has been demonstrated
using the L2 protein as an immunogen (Gambhira et al., 2007;
Pastrana et al., 2005). We previously utilized the murine CVC
system to describe the in vivo mechanism by which antibody-
mediated HPV16 neutralization occurs, as determined by direct
immunization or passive transfer of immune sera (Day et al.,
2010). For neutralization of HPV16 by anti-L1 VLP antibodies, we
found that high antibody levels prevented HPV16 pseudovirus
infection by blocking the initial interaction of capsids with the BM,
while lower antibody levels were associated with capsid binding
to the BM at early time points, but subsequent dissociation of
capsids from the BM and their loss from the tissue. Neutralization
of HPV16 by anti-L2 antibodies was analogous to that of lower
levels of anti-VLP antibodies, in that capsids initially interacted
with the BM, but, coincident with L2 epitope exposure, they
dissociated from the BM and were lost from the tissue.
In the current study, we used passive transfer of immune serum to
study in vivo neutralization of MusPV1 with anti-VLP antibodies and
anti-L2 antibodies, as this approach allowed us to examine the effect of
different antibody levels. After determining the amount of passively-
transferred rabbit anti-VLP antiserum or rabbit anti-L2 antiserum
necessary to completely inhibit infection (data not shown), we used
microscopy to examine anti-VLP neutralization at a saturating dose,
100-fold over the lowest neutralizing dose. At this high dose, anti-VLP
neutralization of MusPV1 appeared to be indistinguishable from that
previously observed for HPV16, as there were few antibody-bound
capsids, and none were associated with the BM, although the pre-
viously documented association with lumenal neutrophils was
observed (Fig. 4B, compare with pre-immune serum in Fig. 4A). When
we examined the localization of the MusPV1 capsids that were
neutralized with a lower dose of anti-VLP antibody, 10-fold higher
than the lowest completely neutralizing dose, the 4 h time point
ﬁndings appeared to be similar to our previous results with HPV16, in
that capsids were associated with the BM (Fig. 4C). However, in tissues
harvested at the 18 h time point, we unexpectedly observed that the
MusPV1 capsids remained associated with the BM. This result, there-
fore, identiﬁes yet another point of divergence from HPV16, where
tissue-associated capsids were not detectable at 18 h post-infection.
Consistent with the ability of this antibody dose to neutralize infection,
no transfer of MusPV1 to the epithelial cells could be detected
(Fig. 4D), despite the strong BM binding.
The results of the anti-L2 neutralization of MusPV1 were also
dramatically different from the parallel HPV16 experiment. Similar
to what was seen with the lower amount of anti-VLP serum, the
antibody-bound MusPV1 capsids were associated with the BM at
4 h (Fig. 4E) and did not dissociate from the BM at the later time
point (Fig. 4F), and there was no detectable transfer of the capsids
from the BM to the epithelial cells. We conclude that, compared
with HPV16, the MusPV1 capsids are more strongly associated
with the BM, or do not lose afﬁnity following furin cleavage.
Conditions that prevented association or caused HPV16 displace-
ment from the BM including; heparin, furin inhibition and anti-L2
neutralization, had no effect on MusPV1 BM binding. However, in
all these cases, transfer of the MusPV1 capsids to the overlying
epithelium, or their stable association with it, was prevented.
Ex vivo interaction with human BM
These results raise the possibility that there may be a species-
speciﬁc (or at least species-restricted) non-HSPG component on the
BM that can mediate PV interaction. According to this conjecture,
Fig. 2. Inhibition of MusPV1 and HPV16 infection in vivo. The murine CVC model
was utilized to compare inhibition of MusPV1 infection with HPV16 infection. In all
cases 5 animals were analyzed for each treatment group and the conditions were
performed on at least two separate occasions. Representative experiments are
depicted. Images were taken in the IVIS 100 imaging system using medium binning
and 60 s exposure and analyzed with the Living Image 3.0 software. The IVIS signal
is shown on the Y-axis as the average radiance given in mean p/s/cm2/sr7standard
deviation. The selected area was the similarly placed for all treatment groups. The
effect of heparinase III pretreatment on infection is shown in panel A. Panel B
shows the effect of exogenous heparin on PsV infection. The dependence of
infection on furin activity is shown in panel C. hepx¼heparinase III treatment,
hep¼heparin treatment, FI¼treatment with furin inhibitor.
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Fig. 3. Furin-dependent exposure of the N-terminus of MusPV1 L2 in vivo. The effect of furin inhibition on capsid localization was evaluated by harvesting treated tissues at
either 4 h (panel A) or 18 h (panel B) and staining with the rabbit anti-VLP antiserum. BM association is obvious at 4 h, and this capsid association is clearly retained at the
later time point. An antiserum raised against the 17–36 region of the MusPV1 L2 protein was used to evaluate furin dependence of L2 epitope exposure. Panel C shows the
staining of infected tissue with pre-immune serum from the immunized animal. Panels D–F shows staining of infected tissue at 4 h, prior to L2 epitope exposure. No
discernable anti-L2 staining was seen (panel D); however, clear capsid association was demonstrated by anti-VLP staining (panel E). The merged image is shown in panel F.
Staining of infected tissue at 18 h post-instillation is shown in the remaining panels. The anti-L2 staining (panel G) is colocalized with MusPV1 capsids on the BM (panel H),
as expected, and is also positive in the epithelium immediately above. The merged image is shown in panel I. However, under conditions of furin inhibition no L2 staining is
evident (panel J) whereas capsids are still detectable (panel K). The merged image is shown in panel L.
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the species-speciﬁc interaction was revealed by the use of the
homologous murine infection model used in this study, whereas it
was not evident in the previous work investigating the heterologous
HPV16 infection of murine tissue. As we are not able to perform
homologous in vivo experiments with HPV16, we decided to
examine the BM interactions with an ex vivo tissue matrix com-
posed of donated human dermal tissue. This matrix, AlloDerm, is
used for regenerative tissue repair in human patients and has been
processed to remove the epithelial cellular components while
preserving the biochemical and biomechanical properties of the
BM, although it is unknown what conformational changes to
individual proteins may occur during processing. When we exam-
ined the ability of HPV16 capsids to interact with the AlloDerm BM,
we found that the capsids bound well to the BM side of this tissue
(Fig. 5A) and that binding was prevented by the addition of
exogenous heparin (Fig. 5B). No binding to the dermal side of
AlloDerm was observed (data not shown). This result supports the
idea that HPV16 binds initially to an HSPG component on human
BM. Additionally, we conﬁrmed that AlloDerm BM could support the
furin-dependent conformational change of L2, as observed on the
murine tissue in vivo, in that addition of exogenous furin resulted in
exposure of the L2 N-terminus, as indicated by the increased binding
of an anti-L2 aa17–36 antiserum (data not shown).
We also examined the binding of MusPV1 to this tissue. The
results indicated that it bound strongly (Fig. 5C); however, this
binding could be prevented by exogenous heparin (Fig. 5D), in
contrast to what we observed with the homologous in vivo
system. Possibly the non-HSPG moiety that MusPV1 initially
Fig. 4. Antibody inhibition of MusPV1 in vivo. The effect of passive transfer of either preimmune serum or immune serum against MusPV1 L1 VLPs or L2 was assessed.
Preimmune serum, shown in panel A, does not affect the distribution of MusPV1 capsid binding at 4 h. However, the transfer of high levels of anti-VLP serum prevents
association of capsids with the BM at this timepoint as shown in panel B. As previously documented (Day et al., 2010), neutralized PsV is bound to extra-epithelial cells,
primarily neutrophils, present in the tissue lumen. Transfer of lower levels of anti-VLP serum does not prevent the association of capsids with the BM at 4 h (panel C) and at
18 h this association is clearly present, with no transfer to the overlying epithelium (panel D). The effect of transfer of anti-L2 immune serum is shown in panels E and F. At
4 h strong association to the BM is evident (panel E). At 18 h the capsids are still clearly bound to the BM with no epithelial transfer evident (panel F).
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interacts with is altered by the Alloderm isolation procedure.
Alternatively, this result could indicate that MusPV1 interacts with
human BM via HSPGs. To distinguish between these possibilities,
we utilized the Alloderm preparation procedure to isolate desic-
cated BM from murine vaginal tissue. This allowed us to separate
processing artifacts from putative species-speciﬁc differences.
When we used this in vitro murine material, the binding behavior
of both viruses was identical to that observed with the in vivo
murine tissue. As shown in Fig. 5E, HPV16 bound strongly to the
BM, and this binding was abrogated by exogenous heparin (5F).
Likewise, MusPV1 bound well (5G) in a manner that cannot be
prevented by heparin addition (5H). The BM is costained for
nidogen to indicate that BM components were intact in all tissues
examined. Laminin 332 expression was also unaffected by the
processing (data not shown). Therefore, we believe that the
processed tissues, despite the desiccation and rehydration proce-
dure, act as acceptable surrogates for in vivo BM. The mechanism
of HPV16 binding appears similar to that described for the murine
CVC system for both human- and murine-derived ex vivo matrices.
The binding characteristics of MusPV1 are similar between in vivo
murine tissue and the murine-derived processed ex vivo BM;
however, its interaction with Alloderm, the human BM, was
distinct in that it was inhibited by exogenous heparin. This
difference is likely indicative of a species-speciﬁc interaction, but
we cannot eliminate the possibility that processing differences
between the BM preparations may account for the difference.
In vitro interaction of MusPV1 with ECM
As the mode of initial interaction of MusPV1 with host tissue is
clearly distinct from that of HPV16, we wanted to determine if
these differences extend to in vitro interactions. As stated pre-
viously, we observed differences in HPV16 interactions in vitro and
in vivo that cast doubt on the biological relevance of some of the
in vitro observations. However, at present, cultured cell lines are
the most tractable platform for investigating virus entry and
trafﬁcking, so it is important to understand the parameters of
viral interaction in this context. We ﬁrst examined the interaction
Fig. 5. Analysis of ex vivo BM binding of HPV16 and MusPV1 capsids. Strips of AlloDerm matrix (panels A–D) and murine vaginal matrix (panels E–H) were hydrated in PBS
prior to capsid addition. HPV16 was added to the matrix shown in panels A, B, E and F. MusPV1 was added to the matrix shown in panels C, D, G and H. Exogenous heparin
(100 μg/ml) was added coincident with the PsV to the matrix shown in panels B, D, F and H. Following tissue processing and sectioning, the bound PsV was detected with the
appropriate rabbit anti-VLP antiserum. Nidogen staining is shown in the red channel for the murine tissues. DAPI nonspeciﬁcally binds to the dermal matrix which
conveniently delineates the tissue borders.
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Fig. 6. Analysis of ECM binding of HPV16 and MusPV1 capsids. HaCaT or Pam212 cells were plated onto glass coverslips and ECM prepared by cellular lysis after 24 h of
cellular growth. For the experiments shown in panels A–F, HPV16 and MusPV1 capsids were added together to the ECM preparation. HPV16 capsids were detected with a rat
anti-HPV16 VLP antiserum. MusPV1 capsids were detected with a rabbit anti-MusPV1 VLP antiserum. Individual virus incubations, stained with both antibodies revealed no
recognition of the other type (data not shown). HaCaT ECM is shown in panels A–C. The anti-HPV16 staining is in panel A; the anti-MusPV1 staining is shown in panel B.
Panel C shows the merged image. Panels D–F show the same experimental layout for Pam212 ECM. For panels G, H (HaCaT) and J, K (Pam212), the indicated cell line was
grown in medium containing sodium chlorate for 24 h prior to replating in sodium chlorate onto coverslips 24 h prior to ECM preparation. The binding of HPV16 is shown in
panels G and J. The binding of MusPV1 is shown in panels H and K. Exogenous heparin was added with MusPV1 to HaCaT ECM; the staining is shown in panel I. Note the
shifted localization as compared with panel B. HPV16 binding to Pam212 in the presence of exogenous heparin was also evaluated (panel L).
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of MusPV1 with extracellular matrix (ECM) secreted from cultured
keratinocytes. We used matrices, prepared directly on coverslips
according to standard methodology, from either HaCaT cells or
Pam212 cells, human and murine keratinocytes, respectively, and
determined the extent of ECM binding of both HPV16 and MusPV1
by microscopy. Pseudovirions of both types were simultaneously
applied to the ECM. Following this incubation, unbound particles
were removed by extensive washing. The residual bound PsV
particles were coincidently visualized with rabbit anti-MusPV1
L1 and rat anti-HPV16 L1 antisera. As shown in Fig. 6, HPV16 and
MusPV1 appear to bind subtly different, partially overlapping
regions in both of the ECM preparations. The ECM derived from
HaCaT cells is shown in panels A–C, and Pam212-derived ECM in
panels D–F.
Sodium chlorate treatment during cell growth prevents protein
sulfation (Baeuerle and Huttner, 1986). Therefore ECM prepared
from sodium chlorate-treated cells lack sulfated GAGs. To determine
if a sulfated protein is involved in ECM binding of the PV prepara-
tions, we prepared ECM from both cell types treated with this
compound. Although this treatment had no noticeable effect on the
interaction of HPV16 with HaCaT-derived matrix (Fig. 6G), it
completely prevented the association of MusPV1 with HaCaT matrix
(Fig. 6H). Conversely, sodium chlorate-treated Pam212-derived ECM
was unable to support HPV16 binding (Fig. 6J), whereas no effect on
MusPV1 binding was observed (Fig. 6K). To conﬁrm loss of HS
moieties under these growth conditions, we stained the isolated
ECM with an anti-HS antibody. Complete loss of HS reactivity was
observed (Supplemental Fig. 3). We also examined the ability of
exogenous heparin to block the ECM interaction in the two instances
where sodium chlorate affected binding. ECM was prepared under
normal growth conditions (no chlorate), and exogenous heparin
(100 μg/ml) was added during the PsV incubation. The heparin was
found to affect the interaction of the MusPV1 virions with the HaCaT
ECMwithout ablating it. Comparison of panels 6B and 6I reveals that
heparin-bound MusPV1 particles are associated with the ECM in a
more globular pattern than the untreated particles, possibly reﬂect-
ing capsid aggregation. Western blot analysis of bound particles did
not show a signiﬁcant diminution of signal in the presence of
heparin (data not shown). In contrast, exogenous heparin comple-
tely prevented the interaction of HPV16 PsV with Pam212-derived
ECM (Fig. 6L). This result was also conﬁrmed by Western blot
analysis (data not shown).
We previously found that HPV5 could interact with heparin,
but that heparin did not prevent either in vitro or in vivo infection.
HSPG interaction could only be conﬁrmed for HPV5 by cleavage of
HS groups with heparinase treatment prior to infection (Johnson
et al., 2009). Therefore, as we found that MusPV1 binds to a
sulfated protein within the HaCaT ECM, we also examined the
binding following heparinase III digestion of the ECM. We found
that this treatment completely blocked this interaction, whereas
the interaction with Pam212 ECM was unaffected (data not
shown). This result indicates that MusPV1 binds to HSPG within
HaCaT ECM, although this interaction cannot be blocked with
exogenous heparin. A primary receptor for MusPV1 on Pam212
ECM is not HSPG, nor any other sulfated protein.
Owing to the divergent results between HPV16 and MusPV1
obtained with heparin inhibition in vivo and with binding to ECM,
we examined the inhibition of in vitro infection with heparin over a
range of concentrations (Fig. 7). Heparin treatment completely
inhibited MusPV1 infection of HaCaT cells, whereas Pam212 infec-
tion was only inhibited 60% at the highest concentration of heparin,
at over 109 M excess of heparin/VLP. We also examined the ability of
exogenous heparin to prevent infection of two other murine
keratinocytes lines, 308 and S1. MusPV1 infection was also poorly
inhibited in these lines. Complete abrogation was not attainable
even at the highest concentration of heparin, similar to that seen
with MusPV1 infection of the Pam212 cell line. In contrast, HPV16
PsV infection of the three murine keratinocyte-derived cell lines was
completely inhibited by heparin treatment. We did not obtain
complete inhibition of HaCaT cell infection by HPV16 in this
experiment, although in previous assays, both published and
unpublished, complete inhibition has been observed at high con-
centrations (Fig. 7) (Drobni et al., 2003; Johnson et al., 2009).
Taken together, these results indicate that MusPV1 pseudovirions
bind to all murine matrices – in vitro ECM, in vivo BM, and ex vivo
dehydrated BM – in an HSPG-independent manner, whereas their
association to human ECM/BM is HSPG-dependent. In contrast,
HPV16 interacts with murine ECM/BM and ex vivo BM in an
HSPG-dependent manner. However, there is a discrepancy between
its interaction with ex vivo human BM, which is HSPG-dependent,
and the HSPG-independent binding to HaCaT ECM.
MusPV1 and HPV16 entry pathways
To determine if these differences in initial host interactions
resulted in differences in intracellular trafﬁcking, HaCat cells were
simultaneously infected with HPV16 and MusPV1 PsV, and the
localization of each PsV was determined by detecting anti-HPV16
in the red channel and anti-MusPV1 in the green channel. As
shown in Fig. 8A, distinct binding patterns were observed along
Fig. 7. Heparin inhibition of HPV16 and MusPV1 infection of human and mouse
keratinocyte lines. The ability of heparin to prevent in vitro keratinocyte infectionwas
evaluated. A two-fold titration series of heparin starting from a concentration of 1 mg/
ml was added to cells coincidentally with a PsV preparation containing a packaged
GFP reporter plasmid. Percent inhibition of infection, as measured by GFP expression,
is shown normalized to infection without heparin addition. All conditions were
performed in triplicate. Infection with HPV16 is shown in the upper panel (A) and
infection with MusPV1 is shown in the lower panel (B). As indicated, infection of
HaCaT cells is demarcated by the line with black circles; infection of Pam212 cells is
indicated by the line with black squares. 308 cell infection is represented by open
circles, and infection of S1 cells is represented by open squares.
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the peripheral cell borders for the two virus types. The HPV16
capsids appear to be more ECM-associated, whereas the MusPV1
capsids are more associated with the cell body. However, a
different focal plane of the same cell illustrates that the viruses
appear to have substantial intracellular colocalization, indicating a
possible convergence during endocytosis. Fig. 8B shows the
merged image, which is separated to show HPV16 in Fig. 8C and
MusPV1 in Fig. 8D. We observed similar results after co-infection
of Pam212 cells (data not shown).
To further investigate the entry processes, we compared the
inhibition proﬁles of a panel of biochemical inhibitors on virus infec-
tion in both cell types. Pharmacological Inhibition of HPV16 PsV
infection has been extensively examined in previous studies with
the conclusion that this virus enters both HeLa and HaCaT cells via
an atypical pathway resembling macropinocytosis (Schelhaas et al.,
2012; Spoden et al., 2008). Here, we examined two inhibitors targe-
ting this pathway: EIPA, which affects the sodium proton exchanger, a
hallmark of macropinocytosis and calphostin C, which affects protein
kinase C (PKC). Additionally, we examined the effect of genistein, an
inhibitor of tyrosine kinase signaling; AG1479 and PD168393, both of
which prevent activation of the EGF receptor kinase; and a furin
inhibitor, which prevents furin cleavage of L2 at the cell surface. We
also evaluated whether the later event of passage through the endo-
somal system was conserved in these cell types, by evaluating the
effects of baﬁlomycin A and NH4Cl, both of which raise endosomal
pH. Traverse through the acidic endosomal system is well establis-
hed to be a requirement for successful infection by several PVs,
including HPV16 (Day et al., 2003; Laniosz et al., 2009; Muller et al.,
2014; Selinka et al., 2002; Smith et al., 2008). The results from
these analyses are shown in Fig. 9A and B for HaCaT and Pam212,
respectively. It was evident that HPV16 and MusPV1 were affected
similarly with all examined inhibitors irrespective of the cell line.
However, it was also apparent that HaCaT and Pam212 cell lines
exhibited different inhibition proﬁles. EIPA affected infection of
Pam212 cells to a lesser extent than that observed for HaCaT cells,
and calphostin C, another inhibitor of macropinocytosis, had no effect.
The discrepancy between cell lines was also evident for the EGFR
kinase inhibitors. Both AG1478 and PD168343 inhibited infection of
the two virus types in HaCaT cells, but increased infection (up to two-
fold) in Pam212 cells. Genistein inhibited infection in both cell types,
albeit to a lesser extent in Pam212, indicating a general requirement
for RTK activation. Prevention of furin cleavage, also a cell surface
event, completely abrogated infection of both PV types in both cell
lines. Likewise, inhibition of endosomal trafﬁcking of the PsV by
increasing endosomal pH prevented infection of both cell types.
Because of this unexpected variation, we extended the infection
analysis to include the two other murine keratinocyte cell lines studied
earlier, 308 and S1. The 308 line has a less transformed phenotype
than Pam212 cells, and S1 is considered relatively untransformed (Suh
et al., 2004; Yuspa et al., 1980; Yuspa and Morgan, 1981). As observed
with HaCaT and Pam212, HPV16 and MusPV1 shared biochemical
inhibition proﬁles for these two additional cell lines (Fig. 9C and D).
Surprisingly, both of these lines were more similar to HaCaT than to
Pam212 cells in their inhibition proﬁles. They were sensitive to macro-
pinocytosis inhibition, genistein blocked infection of both viruses as
efﬁciently as in HaCaT cells, and endosome acidiﬁcation and furin
cleavage activity was essential for infection in all instances. EGFR
kinase inhibition induced a marginal reduction in 308 cells for both
viruses, while it inhibited infection of S1 cells by approximately 50%
for both viruses.
Fig. 8. Visualization of internalized capsids in HaCaT cells. HPV16 and MusPV1 were co-incubated with HaCaT cells for 6 h and capsids were detected with rat anti-HPV16 (red)
and rabbit anti-MusPV1 (green). A focal plane at the cell surface of the merged image is shown in panel A. A focal plane showing internalized virus in the same cells is shown in
panel B. The majority of the colocalized particles are not on the cell surface. The unmerged images of panel B are shown in panels C and D. The size bar indicates 10 μm.
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The inhibition proﬁle of the PV PsV in Pam212 cells was thus
unique, as the other two murine cell lines resembled HaCaT cells,
except for the effect of EGFR kinase inhibitors. As this is the
distinguishing feature of the entry pathways, we wanted to ensure
that EGFR-dependent activation and signaling pathways were active
in these cell lines. Therefore, we examined the accumulation and
distribution of phosphorylated ERK1/2 proteins following addition of
either exogenous EGF or HPV16 capsids. Following activation, the
ERK1/2 complex migrates to the nucleus. This nuclear transport is
dependent upon phosphorylation and is a commonly used marker of
activation. This has been shown for EGF stimulation and HPV16 has
been previously demonstrated to act similarly (Surviladze et al.,
2012). The results of this experiment are shown in Fig. 10. HaCaT cells
are shown in the ﬁrst row from the top (panels A–D), Pam212 cells in
the second row (panels E–H), 308 cells in the third row (panels I–L),
and S1 cells in the bottom row (panels M–P). For each cell line, the
phosphorylated ERK1/2 staining of unstimulated cells is shown in
the ﬁrst panel. The second panel shows the phosphorylated ERK1/2
staining of cells that were stimulated by EGF addition. The staining of
cells that were pretreated with the EGFR kinase inhibitor PD168343
prior to EGF addition is shown in the third panel. The effect of HPV16
addition to the distribution of phosphorylated ERK1/2 is shown in
the fourth panel. In all cases, the addition of EGF resulted in an
increase in nuclear phosphorylated ERK1/2, which was prevented by
the prior addition of either EGFR kinase inhibitor. However, only the
HaCaT cells responded to addition of HPV16 (panel D). This nuclear
redistribution of phosphorylated ERK1/2 was prevented by addition
of either PD168343 or AG1478 (data not shown). None of the murine
keratinocyte lines showed a shift in either intensity or distribution of
ERK species following HPV addition, and the treatment with either
PD168343 or AG1478 prior to HPV16 addition was unremarkable
(data not shown).
Therefore, we conclude that Pam212 cells endocytose PV PsV
via a non-macropinocytotic mechanism, possibly owing to its
transformed phenotype, whereas the other keratinocytes exhib-
ited similar uptake pathways. The sole distinction between HaCaT
and the two murine lines was the independence from EGF
receptor signaling for 308 and S1 infection.
Discussion
We recently reported that PsV of diverse PV types exhibited no
selectivity in early events of infection at either mucosal or squamous
epithelial sites, strongly implying that downstream post-entry
events are responsible for the observed differences in PV tissue
tropism (Handisurya et al., 2012). Speciﬁcally, we found that murine
cutaneous and genital tissues were similarly permissive for PsV of
multiple HPV types, including HPV16, MusPV1, and other animal PV.
Despite this shared activity, we have shown in this study that HPV16
and MusPV1 appear to have evolved to interact with different host
cell proteins. Although this difference in binding does not affect their
intrinsic tropism, it could be an important consideration in inter-
preting the results of model systems based on heterologous species.
We initially focused this analysis on the in vivo interactions of
MusPV1 with host BM and cells in the murine CVC model (Roberts
et al., 2007). Although MusPV1 was originally isolated from cutaneous
lesions (Ingle et al., 2011), it has since been demonstrated to also infect
mucosal sites including vaginal and anal epithelium, and sites at
mucocutaneous junctions such as the muzzle, thus legitimizing the
CVC model for MusPV1 infection analysis (Cladel et al., 2013; Sundberg
et al., 2014). This dual tropism resembles that of some common HPVs,
such as types 6 and 11, which infect both epidermal andmucosal genital
sites. HSPGs have been well established to be an initial attachment
Fig. 9. Proﬁles of biochemical inhibition of HPV16 and MusPV1. Keratinocyte cell
lines were treated with biochemical inhibitors of previously reported HPV16
trafﬁcking pathway. The effect of HPV16 and MusPV1 PsV infection was deter-
mined by ﬂow cytometric analysis of GFP expression. The percent inhibition is
shown for each condition and cell line. Each condition was performed in triplicate
and replicated in separate experiments three times. All data are shown. The
numbers on the X axis represent the different inhibitors as follows: 1) AG1478. 2)
PD168343. 3) genistein. 4) EIPA. 5) calphostin C. 6) Furin inhibitor I (decanoyl-
RVKR-cmk). 7) baﬁlomycin A. 8) NH4Cl.
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receptor for multiple PV genotypes in vitro (reviewed in Buck et al.
(2013) and Sapp and Day (2009)), and may also contribute to infection
via the binding of soluble complexes with growth factors (Surviladze et
al., 2012). We have previously shown that BM binding is critical for
in vivo infection of HPV16, HPV31 and HPV5 (Johnson et al., 2009). In
that analysis, it became clear that the interaction of heparin and its
derivatives with HPV5, a beta type HPV, differs from their interaction
with two alpha types HPV16 and HPV31, as different heparin variants
affected the alpha and beta types in dissimilar ways. Most strikingly,
the heparin derivative (heparin H4784) most commonly used to block
alpha PV infection did not prevent HPV5 infection, although it was
shown to bind to the capsid. However, for all the HPV types exami
ned in vivo, enzymatic removal of the BM HSPG moieties with
heparinase prevented BM binding and subsequent infection. Consistent
with the importance of BM association, inhibition of infection by the
various heparin derivatives paralleled their relative ability to inhibit
BM association.
In the current study, we report what appears to be an even
greater difference in the mode of the interaction of MusPV1 with
host tissue. Interestingly, the interaction of MusPV1 with murine
Fig. 10. Stimulation of phosphorylated ERK species in keratinocyte cell lines. The ability of EGF and HPV16 to stimulate upregulation and nuclear localization of
phosphorylated ERK1/2 was evaluated in the four keratinocyte cell lines. HaCaT cells are shown in panels A–D; Pam212 cells are in panels E–H; 308 cells are in panels I–L;
and S1 cells are in panels M–P. The unstimulated cells are shown in the ﬁrst column (panels A, E, I and M). The EGF-stimulated cells are shown in the second column (panels
B, F, J and N). Note that the nuclear signal is increased with this treatment for all cell lines. The addition of PD168343 decreases the signal for all lines as shown in the third
column (panels C, G, K and O). Phosphorylated ERK1/2 is increased in HaCaT cells after HPV16 addition (panel D) anti L1 staining is shown in the red channel. This increase is
not mirrored in the murine keratinocyte cell lines (panels H, L and P). To allow better appreciation of the nuclear ERK1/2 signal an inset is shown in each panel showing a
stained nucleus without the DAPI signal.
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BM is not through HSPG, in that BM binding is not disrupted by
either exogenous heparin or enzymatic digestion with heparinase.
However, there is apparently an HSPG-dependent step later in infe-
ction, as exogenous heparin prevents association of the MusPV1
capsids with the epithelial cells. This characteristic is, thus far,
unique to MusPV1. Two possible explanations are that there is an
essential “handoff” from an HSPG intermediate binding partner to a
cellular receptor or an additional essential conformational change
mediated by an HSPG interaction that allows capsid binding to the
epithelium. MusPV1 is the only virus from the Pi genus that has
been examined for receptor usage. Perhaps this genus, which con-
tains the majority of the rodent PV types, will generally display this
mechanism of host interaction.
Before concluding that this difference is physiologically relevant,
we tried to rule out the possibility that HSPG-independent BM
binding might be a general feature of BM binding by a homologous
PV species, as the previous in vivo analyses of the HPVs have been
carried out in mice, a heterologous species for HPV. To address this
concern, we examined AlloDerm, an acellular human dermal tissue
that retains the biochemical and biomechanical properties of the BM.
Additionally, to control for processing artifacts due to the Alloderm
isolation procedure, we replicated the process with murine vaginal
tissue, which allowed a direct comparison of experiments performed
with processed tissue to the in vivo data obtained from the same
tissue source. Using the ex vivo matrices, we were able to conﬁrm
HSPG-dependent BM association for HPV16 to both human- and
murine-derived BM, whereas MusPV1 exhibited HSPG-independent
binding to murine tissue and HSPG-dependent binding to the
human-derived BM. Thus, the ex vivo matrix results support the
conclusion that the observed binding differences are an intrinsic
property of HPV16 versus MusPV1 capsids.
The HPV16-related data were important for our continued con-
ﬁdence that the mouse CVC model is a legitimate in vivo system for
examining early events in HPV infection. The AlloDerm results also
reafﬁrm our observations that the ECM secreted by HaCaT cells
differs in its post-translational HSPG modiﬁcations from the ECM
found on BM in vivo. As previously described, with HaCaT ECM,
HPV16 does critically interact with HSPG, but the majority of the
actual attachment is through laminin 332 (Cerqueira et al., 2013;
Culp et al., 2006; Selinka et al., 2007). As in vivo BM binding of
HPV16 can be completely prevented with heparin or heparinase,
laminin 332 does not apparently contribute in that context. In vitro
experiments indicated that laminin 332 does not play a role in
MusPV1 binding to HaCaT ECM (data not shown).
In addition, MusPV1 attachment to ECM/BM from human tissue
is HSPG-dependent, including its interaction with HaCaT-derived
ECM. Although exogenous heparin could not prevent this binding, it
clearly affected the distribution of the bound capsids, and hepar-
inase digestion completely abrogated it. This distinction between the
ex vivo human tissue, whose MusPV1 binding is HSPG-independent,
and HaCaT ECM is further evidence that the HSPG modiﬁcations on
HaCaT ECM differ from the in vivo situation. We conclude that
MusPV1 utilizes an attachment moiety on the murine BM and ECM
that is distinct from HSPG, the component engaged by all HPVs
examined to date. The ﬁnding that diverse PV types have evolved to
differently engage the host BM underscores the importance of BM
attachment in the initiation of the PV lifecycle.
Another observed in vivo difference in BM binding between
MusPV1 and HPV16 was seen under several conditions where PV
binding occurs, but the transfer to the target epithelial cell is
prevented, that is MusPV1 is retained on the BM, while HPV16 is
lost from the BM. The conditions that are permissive for binding but
non-permissive for epithelial transfer, which are common to both
MusPV1 and HPV16, include the inhibition of furin cleavage,
neutralization by low levels of L1 antibodies, and neutralization by
L2 antibodies. We have previously theorized that HPV16 is lost from
the BM under these conditions because of a putative decrease in its
afﬁnity for the BM, concomitant with a block in its association with
the epithelial cell. Perhaps MusPV1 exhibits a stronger afﬁnity to its
non-HSPG binding partner on the BM than HPV has for BM HSPGs,
so preventing its interaction with the epithelium (or second BM
interactor) results in continued BM association.
These observations have implications for the interpretation of a
previous study of HPV16 in vivo antibody inhibition (Day et al.,
2010). In that work, we suggested that the loss of antibody-bound
capsids from the BM following low level anti-VLP neutralization or
anti-L2 neutralization was attributable to loss of afﬁnity for the
BM, but we could not eliminate the possibility that antibody-
bound virus was primarily removed from the BM by neutrophil
scavenging via Fc recognition. Given the retention of antibody-
bound MusPV1 capsids from the BM at the 18 h time point, it is
unlikely that neutrophils were primarily responsible for the loss
observed with HPV16. The discrepancy between the two viruses is
likely due to differences in BM afﬁnity. We are currently trying to
identify the high afﬁnity, non-HSPG binding partner for MusPV1
on the BM. It might be the same moiety that mediates the HSPG-
and sulfation-independent MusPV1 interaction with Pam212 ECM.
Despite the differences in the initial interacting partners found
for HPV16 and MusPV1, both viruses appear to use the same
endocytic pathways. The biochemical inhibition proﬁles of the two
viruses were the same for the four murine or human keratinocyte
cell lines examined. Previous analyses have not identiﬁed differences
in the entry pathways of various HPV types (Spoden et al., 2013), but
this is the ﬁrst parallel examination between PVs that with this
degree of evolutionary divergence. The observation that these two
PV share their endocytic itineraries supports the possibility that all
PV types will be similar in this regard.
However, interesting differences among the cell lines did emerge.
Signaling through the EGF receptor has been described to occur soon
after PV binding to HaCaT cells, and inhibition of this pathway
prevents infection of both HaCaT and HeLa cells (Schelhaas et al.,
2012; Surviladze et al., 2012). We found that this pathway was
neither activated nor necessary during PV infection of the murine
keratinocytes, although the pathway was shown to be intact in these
cells. Therefore, in cultured cells, activation of this pathway cannot
be considered an obligatory requirement for PV infection, although
it may be critical for infection of human cells. Despite this distinc-
tion, HaCaT, 308 and S1 keratinocytes apparently share a common
entry portal for PV, as all other inhibitors examined affected entry of
both viruses similarly for these cell lines.
The entry pathway utilized by PV in Pam212 cells remains to be
determined. Although inhibition of sodium–proton exchange via
EIPA decreased infection somewhat, corroborating biochemical
evidence of inhibition with calphostin C that should affect macro-
pinocytic uptake was not observed. EIPA has multiple off-target
effects that can affect intracellular trafﬁcking and the cytoskeleton,
which may account for the mild inhibition observed (reviewed in
Ivanov (2008)). The only strong inhibition of Pam212 infection was
found with furin inhibition and the two endosomal acidiﬁcation
inhibitors, NH4Cl and baﬁlomycin A.
In summary, the Pi PV type, MusPV1 has evolved a distinct
mechanism to mediate its initial interaction with host tissue. This
difference is evident through analysis of both in vivo and in vitro
systems. However, phylogenetically distant PV types converge to
utilize the same endocytic pathway. Our analysis was consistent with
a macropinocytic-like mechanism in HaCaT cells and the two murine
keratinocyte lines, 308 and S1, but this pathway is apparently not
used in the Pam212 cell line. Our ﬁnding that PVs seemingly utilize
distinct entry pathways in different keratinocyte cell lines raises a
cautionary note. It underscores the importance of cell line selection
in the analysis and the interpretation of studies of PV infection and
infection inhibitors. Most importantly our data reinforce the idea
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that initial access to the host BM and attachment at this site is
universally important for PV infection.
Materials and methods
Pseudovirus production
The expression plasmids, p16Llw or pMuLlw, which bicistronically
express both capsid proteins for HPV16 and MusPV1, respectively,
were used to produce PsV. PsV was produced, matured and puriﬁed
as previously described (Buck et al., 2004, 2005a). PsV was conﬁrmed
to be essentially free of protein impurities by staining of electro-
phoresed samples. Representative examples the pfwB preparations
are shown in Supplemental Fig. 1. To examine in vivo infection,
pseudovirions were produced with the packaged pcLucf plasmid,
which encodes ﬁreﬂy luciferase. For in vitro infection assays PsV was
produced with the GFP-expression plasmid, pfwB. In vitro micro-
scopic analysis was performed with pseudovirions containing the
PYSEAP plasmid. All plasmids are described on the laboratory
website (http://home.ccr.cancer.gov/lco/plasmids.asp). Puriﬁed PsV
preparations were characterized for their infectivity and L1 levels.
PsV amounts used for all assays were based on L1 content.
Inhibitors
The following inhibitors were examined at the listed concentra-
tion for their effects on PV infection: AG1478 2 μM (Calbiochem);
baﬁlomycin A 100 nM (AG Scientiﬁc); Calphostin C 625 μM (Sigma);
EIPA 5 μM (Sigma); Furin inhibitor I (decanoyl-RVKR-cmk) 2.5 μM
(Calbiochem); genistein 150 μM (Sigma); NH4Cl 20 mM (Sigma);
PD168343 500 nM (Calbiochem). In addition, heparin (H4784, Sigma)
was tested by a series of two-fold serial dilutions, starting from an
initial concentration of 1 mg/ml. All experiments were performed in
triplicate.
Antibodies
Rabbit antisera against MusPV1 capsids the L2 11–885
peptide and the L2 peptide 17–36 have been previously described
(Day et al., 2010; Handisurya et al., 2013). HPV16 capsids were
detected with either a rabbit anti-L1-only VLP antiserum or a rat
anti-L1-only VLP antiserum, as noted for the individual experi-
ment (Johnson et al., 2009; Roden et al., 1996). Antibodies used to
detect MEK1/2 (Cell Signaling) and nidogen (Santa Cruz Biotech-
nology) were obtained from commercial sources. Antibody 10E4
was used to detect HS moieties (Seikagaku). Alexa-ﬂuor-coupled
secondary antibodies were obtained from Invitrogen.
In vitro PsV infection
The murine keratinocyte cell lines, Pam212, 308 and S1, which
were gifts from Stuart Yuspa (NCI, NIH), and the human keratinocyte
cell line, HaCaT, were cultured in DMEM supplemented with 10% fetal
bovine serum (FBS). The murine keratinocytes were all isolated from
the epidermis of Balb/c mice. For inhibitor analysis, cells were seeded
at a density of 8103/well in a 96 well plate. Following overnight
adherence, inhibitors were added to the wells at the concentrations
indicated in the ﬁgure legends, followed by addition of either 0.2 ng
of HPV16 or MusPV1 PsV containing the packaged plasmid, pfwB. The
percentage of GFP-transduced cells was determined by ﬂow cyto-
metric analysis at 48 h following infection. Each condition was tested
a minimum of three times and performed in triplicate on each
occasion. The data were combined into a single ﬁgure.
In vivo PsV infection
Six- to eight-week-old female BALB/cAnNCr mice were obtained
from the National Cancer Institute and handled in accordance with
the NCI approved guidelines. Murine cervicovaginal infection was
performed according to previously published procedures (Kines
et al., 2009). Infection was measured at the indicated times after
PsV delivery, by intravaginally instilling 20 ml of D-Luciferin – Kþ Salt
(0.3 mg, Caliper Life Sciences) followed by imaging with an IVIS 100
(Caliper Life Sciences) as previously described. Despite instillation of
the same amount of PsV, the average radiance reading obtained on
the IVIS 100 varies between experiments. This variability has been
described before, but the reasons are unclear (Handisurya et al.,
2012). Antibody neutralization of infection using passively trans-
ferred anti-MusPV1 VLP serum or 11–885 anti-L2 serum was
performed as previously described (Day et al., 2010). Heparin (Sigma
H4784) and heparinase III (Sigma H8891) and furin inhibitor
(Calbiochem 344930) treatment has also been previously described
(Johnson et al., 2009; Kines et al., 2009). The volume of heparin
(from a 100 mg/ml heparin stock) added to the inoculum was in
excess by a thousand-fold compared to the amount of L1 (ng/μl)
instilled. Typically 500 ng of PsV stock was instilled for infection
analysis and 2.5 μg for binding analysis. For heparinase or furin
inhibitor treatment, prior to pseudovirus instillation, mice were
treated with a 4% nonoxonyl-9 solution in 4% CMC spiked with
either heparinase buffer or heparinase III (1.7 units/mouse) or 6 ml
PC inhibitor (200 μM) (furin inhibitor 1, decanoyl-RVKR-cmk, Cal-
biochem). Five hours following pre-treatment, PsV was instilled
combined with an additional treatment of buffer, heparinase III (3.3
units/mouse) or PC inhibitor (6 ml of 200 μM stock).
For binding analyses, mice were sacriﬁced at the indicated
times following PsV instillation. Genital tracts were excised and
snap frozen in tissue freezing medium (EMS). 6 mm tissue sections
were cryosectioned, transferred to glass slides, ﬁxed for 10 min in
100% ethanol at 20 1C, and processed for immunoﬂuorescent
staining as previously described (Johnson et al., 2009). Brieﬂy,
prior to staining, tissue sections were blocked with 10% donkey
serum in PBS with 0.1% Brij58 for 30 min at room temperature.
Antibodies were diluted in 0.1% Brij and incubated for 60 min at
room temperature. Following staining, sections were mounted
with Prolong Gold mounting solution (Invitrogen).
Immunoﬂuorescent staining
Cells were seeded onto glass No. 01 coverslips in a 24-well plate
at a density of 8104/well and cultured overnight. For intracellular
staining, 20 ng of pseudovirions was added to each well and allowed
to bind and internalize for the time indicated. Following this
incubation, cells were washed three times with PBS, ﬁxed in ice
cold ethanol containing 15 mM glycine, and processed for immuno-
ﬂuorescence using the rabbit anti-MusPV1 serum and rat anti-
HPV16 serum. For visualization of virus binding to ECM, cells were
plated to coverslips as described, but following the overnight
incubation, cells were removed by lysis as previously described
(Day et al., 2007). Virus was applied to the residual ECM for 60 min
at 37 1C to allow binding. Following this incubation, unbound
particles were removed by washing, and the ECM was ﬁxed as
described above. For sodium chlorate treatment, cells were grown
for 24 h with the normal growth medium supplemented with
50 mM sodium chlorate and then replated onto coverslips. Sodium
chlorate treatment was continued during cell adherence overnight.
For detection of phosphorylated MEK1/2, cells were serum
starved for 5 h in Tyrodes buffer containing.05% BSA. For the ﬁnal
hour of this treatment, the EGFR kinase inhibitors, either AG1478 or
PD168343, were added to some wells. Following this step, 100 ng/ml
recombinant EGF, with or without 100 ng/well HPV16 PsV, was
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added to the cultures for 15 min. Murine EGF (R&D Systems) was
used for mouse cells and human EGF (Promega) for human cells.
Following this incubation, the cells were ﬁxed with 2% paraformal-
dehyde for 20 min at room temperature and then processed for
immunoﬂuorescent staining. Following staining, coverslips were
inverted onto DAPI-containing mounting solution (Prolong Gold,
Molecular Probes). All images were acquired with a Zeiss 780
confocal system interfaced with a Zeiss Axiovert 100M microscope.
Images were collated with Adobe Photoshop software.
Capsid binding to acellular basement membrane
Capsid association to human acellular tissue matrix was evaluated
using AlloDerm (LifeCell Corporation). This material possesses a
dermal surface and a BM membrane surface which can be distin-
guished morphologically. Strips of AlloDerm (approximately 1 cm
0.3 cm) were cut and hydrated with PBS for 60 min at room
temperature. Subsequently the PBS was removed, and 50 ng of PsV
was added in DMEM containing 10% FBS, which, as indicated for
some experiments, was supplemented with 100 μg/ml heparin. PsV
was bound to Alloderm for 18 h at 37 1C, which was then carefully
washed three times with PBS, and frozen in tissue freezing medium
(EMS). At this point, they were cryosectioned and processed for
immunoﬂuorescent staining identically to the murine tissues as
described in the previous section. Murine basement membrane
was prepared from vaginal tracts following the procedure described
for Alloderm preparation (US Patent number 5,336,616). Brieﬂy,
excised vaginal tracts were cut longitudinally and placed in a petri
dish on a polyethylene support with the epithelial side facing
upwards. Gauze was placed over the tissue and saturated with PBS
brought to a ﬁnal concentration of 1 M NaCl and incubated at 37 1C
for 20 h. Following this, the gauze was removed and the tissue
washed three times for 5 min with Hank's balanced salt solution
(HBSS). After the third wash the tissue was incubated in HBSS
supplemented with 0.5% SDS and incubated at room temperature
for 1 h. The tissue washed then washed thrice for 5 min with HBSS.
Following the ﬁnal wash the tissue was soaked in a pre-freezing
solution (7% dextran 70 K, 6% sucrose, 6% rafﬁnose, 1 mM disodium
ethylenediamine tetraacetic acid in HBSS) for 15 min at room
temperature. The tissue was then placed on blotting paper with
the BM side down. Gauze was placed over the epithelial side and the
tissue was transferred to a Tyvek bag, sealed and freeze dried. At this
point the tissue was processed as for Alloderm, described above.
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